I agree with everything you said Sean. I see the strength as the opportunity to release the findings and double or triple the stock price at a minimum. Then grow from there. Hell it could be $7-$10 if the results are a home run. Having someone offer before it goes public is genius for the CEO who might be courting CYDY. I realize this is all speculative but it is a hell of a speculation.

This stock price should of took off on the open 350 results but it sure did most likely catch someone’s attention. They know what we have…if what we have is what we believe is excellent results on the 700mg dose. We can’t miss. My only hope is we can either sell one Nash indication to fund all our other indications trials or partner only one indication. I am vehemently opposed to a buy out. We don’t get shit in a buy out. Let’s hope we can just partner… it’s a big change for me. I have always wanted Cytodyn to become their very own pharmaceutical company… getting in on a ground floor with huge growth in a biotech to pharmaceutical is a wet dream… unreal money return. Isn’t that why we are here?